Objectives | Endpoints |
---|---|
FIONA OLE | |
Primary | |
 • To demonstrate that finerenone in addition to an ACEi or ARB is safe when given long term | • Number of participants with TEAEs |
• Change in serum K+ levels from baseline to day 540 ± 7 | |
• Change in SBP from baseline to day 540 ± 7 | |
Secondary | |
 • To assess the long-term treatment effects of finerenone in addition to SoC on proteinuria and kidney function | • Change in UPCR and UACR from baseline to day 540 ± 7 |
• Change in eGFR from baseline to day 540 ± 7 |